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Background: A latent cytomegalovirus (CMV) cause chronic inflammation through undesirable inflation of cell-mediated im-
mune response. CMV immunoglobulin G has been associated with cardiovascular disease and type 1 diabetes mellitus. We evalu-
ated impact of CMV diseases on new-onset type 2 diabetes mellitus (T2DM). 
Methods: From the Korean Health Insurance Review and Assessment Service claim database of entire population with 50 mil-
lion, we retrieved 576 adult case group with CMV diseases diagnosed with International Statistical Classification of Diseases and 
Related-Health Problems 10th Revision (ICD-10) B25 code between 2010 and 2014 after exclusion of patients with T2DM to 
2006. The 2,880 control patients without T2DM from 2006 to cohort entry point were selected between 2010 and 2014 by age, sex 
matching with case group. The subjects without new-onset T2DM were followed until 2015. T2DM, hypertension (HTN), dyslip-
idemia (DYS), and end-stage renal disease (ESRD) were coded as ICD-10. 
Results: The frequency of new-onset T2DM in case group was significantly higher than that in control (5.6% vs. 2.2%, P<0.001). 
The group with T2DM (n=95) had higher incidence of CMV diseases than the group without T2DM (n=3,361) (33.7% vs. 
16.2%, P<0.001). In multivariate regression model adjusted by age, sex, lower income, HTN, and DYS, the incidence rate (IR) of 
T2DM in case group was significantly higher than that in the control group (IR per 1,000, 19.0 vs. 7.3; odds ratio, 2.1; 95% confi-
dence interval, 1.3 to 3.2). The co-existence of HTN, DYS, and ESRD with CMV diseases did not influence the IR of T2DM. 
Conclusion: CMV diseases increase the patients’ risk of developing T2DM.
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INTRODUCTION
The genes of human cytomegalovirus (CMV) chronically ex-
ists in the host myeloid lineage including CD34+ hematopoi-
etic progenitor cells as extrachromosomal plasmid after as-
ymptomatic or self-limited primary lytic infection that occurs 
during childhood and adolescence [1-3]. Unlike other viruses 
of Herpesviridae family, latently established CMV can express 
a handful of transcripts such as latency-associated unidentified 
nuclear antigen (LUNA), UL81-82 antisense transcript, and la-
tency-associated homolog of interleukin-10 (LAcmvIL-10) to-
gether with periodic active replication events during the life-
long [2,4-7]. The outstanding feature of sleepless latency leads 
to the extraordinary expansion of CMV-specific resting effec-
tor memory CD8+ T-cell subpopulation and then chronic in-
flammatory condition as well as dysregulation of host immune 
mechanisms [7-12]. This long-term pathophysiologic mecha-
nisms of CMV acquisition may be the direct cause of chronic 
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inflammatory cardiovascular diseases (CVDs) or autoimmune 
diseases including systemic lupus erythematosus and systemic 
sclerosis [13,14].
Although the pathogenesis of type 2 diabetes mellitus 
(T2DM, non-insulin-dependent diabetes mellitus [DM]) is 
quite complex and involves various cross-linked molecules in-
cluding adipocytokines, receptors, and genetic pathways as 
well as immune system, T2DM seemed to be a fundamentally 
chronic low-grade inflammatory metabolic disease with clini-
cal detrimental effects through various micro- and macrovas-
cular complications [15-21]. Lohr and Oldstone [22] detected 
the CMV immediate-early and late gene products using re-
verse transcription polymerase chain reaction (PCR) and in 
situ hybridization in pancreatic tissues of T2DM patients. Re-
cent studies suggested that viperin (endoplasmic reticulum-as-
sociated, interferon-inducible virus inhibitory protein), which 
is directly induced by CMV, may play a role in lipid and glu-
cose metabolism through interaction with the CMV mito-
chondrial inhibitor of apoptosis (vMIA) protein [23,24].
Considering these molecular biological experiments, we hy-
pothesized that CMV diseases may contribute to the develop-
ment of T2DM. Although only a few clinical studies evaluating 
the association between CMV and T2DM were performed 
nearly 2 decades ago, these studies evaluated CMV seroepide-
miology measured by anti-CMV immunoglobulin G (IgG) an-
tibody test or titer, to determine previous CMV exposure and 
latent status by humoral immunity, with age being a variable 
influence [25-29]. The anti-CMV IgG is not useful for evaluat-
ing CMV-specific cell-mediated immunity (CMV-CMI), 
which plays a major role in immunosenescence and immune 
exhaustion caused by CMV [30]. The active replication of 
whole CMV genes can be delicately categorized into CMV in-
fection and diseases, defined as detection of DNA (DNAemia) 
or competitive virions (viremia) in the peripheral blood and 
cytopathic inflammatory end-organ tissue-invasive disease, 
respectively [30]. The CMV infection or diseases, in relation to 
more powerful immune boosting of CMV-CMI than anti-
CMV IgG serostatus, will better reflect the chronic inflamma-
tory dysregulation phenomenon by CMV-related indirect ef-
fect [30].
The impact of CMV infection or diseases on new-onset 
T2DM had been primarily evaluated as posttransplant DM in 
adult solid organ transplant recipients [31,32]. However, little 
is known about the causal connection of CMV diseases to 
T2DM development in the entire population including both 
transplant and non-transplant patients. Therefore, we per-
formed the general population-based matched case-control 
cohort study in both immunocompetent and immunocom-
promised patients to explore whether the CMV diseases con-
tributes to the development of T2DM.
METHODS
Data resource and management process
Our study used the database warehouse of the Korean Health 
Insurance Review and Assessment Service claims, including 
the detailed information about all kinds of healthcare utiliza-
tion in the entire Korean population [33]. A total of 1,188 un-
duplicated patients with CMV diseases between 2010 and 2014 
were extracted using a unique code (V104) for the relief reduc-
tion of patients with rare intractable diseases, operated by the 
South Korean National Health Insurance Service (NHIS) [33]. 
The healthcare providers should submit the specific document 
to the NHIS to register this particular payment relief. The 
V104 code corresponds to B25 (cytomegalovirus disease), 
B25.0 (cytomegaloviral pneumonitis), B25.1 (cytomegaloviral 
hepatitis), B25.2 (cytomegaloviral pancreatitis), B25.8 (other 
cytomegaloviral diseases), and B25.9 (cytomegaloviral disease, 
unspecified) according to the World Health Organization’s 
2016 International Statistical Classification of Diseases and Re-
lated-Health Problems 10th Revision (ICD-10). To apply the 
V104 code, the clinicians should confirm the CMV diseases 
through histopathological exam, culture, shell viral assay, and 
pp65 antigen test. The presumptive or suspected diagnosis 
with imaging studies or clinical decision is not permissible. 
The V104 code does not include congenital CMV infection 
(ICD-10 code: P35.1) and cytomegaloviral mononucleosis 
(ICD-10 code: B27.1). The study was approved with waiver of 
informed consent by the Institutional Review Board of Gang-
nam Severance Hospital (IRB no. 3-2017-0341) and the NHIS. 
This study was performed according to the Declaration of Hel-
sinki, the ethical principles for medical research involving hu-
man subjects.
Study design and patient selection
We performed the whole population-based matched case-con-
trol cohort study. The patients with V104 code of CMV diseas-
es comprised the case group and those without this code com-
prised the control group. Five hundred and seventy-six case 
patients of the 1,188 with CMV diseases were finally selected 
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between 2010 and 2014 after excluding 285 patients with pre-
vious T2DM before first CMV diagnosis date back to 2006 and 
another 327 who were aged <20 years. The 2,880 control pa-
tients without T2DM between 2006 and cohort entry point 
were randomly stratified matched by age and sex with the case 
patients in the same cohort entry year, with a 5:1 ratio. This co-
hort start and end date were January 1, 2011 and December 31, 
2015. The event in the cohort was the development of new-on-
set T2DM in both case and control group. If subject had the 
event, their follow-up were ceased. All subject without event 
were followed until December 31, 2015. If patients were died 
before event occurrence, they were censored (Fig. 1). 
Definition
Lower income status was defined as an annual household in-
come of lower than 25% based on the results of the 2010 South 
Korea Population and Housing Census. Recurred or refractory 
CMV diseases cases were defined as patients who received re-
peat treatments of ganciclovir and/or valganciclovir between 
30 days and 1 year after the first CMV diagnosis [34]. We sim-
ply expressed the refractory or recurred disease as refractory 
CMV diseases. Chronic medical diseases were matched with 
the ICD-10 code of T2DM (E11–E14), hypertension (I10–I13 
and I15), dyslipidemia (E78 including E78.0–E78.9), chronic 
obstructive pulmonary disease (COPD) (J44 including J44.0, 
J44.1, J44.8, and J44.9), ischemic heart diseases (IHDs) (I20-
I25), cerebral infarction (I63, I64), heart failure (HF) (I50), and 
end-stage renal disease (ESRD) (N18.5). For T2DM diagnosis, we 
additionally used the anti-diabetic drug description with codes of 
insulins, sulfonylureas, metformin, meglitinides, thiazolidine-
diones, dipeptidyl peptidase-4 inhibitors, and α-glucosidase in-
hibitors along with above ICD-10 codes [35].
Statistical analysis
We used the McNemer test and paired t-test to compare the 
nominal and continuous variables between the two groups, re-
spectively. We performed the multivariate logistic regression 
analyses with model 1 (M1, not adjusted), model 2 (M2, adjust-
ed by age and sex), and model 3 (M3, adjusted by age, sex, low-
er income status, hypertension, and dyslipidemia) to evaluate 
the impact of adult CMV diseases on new-onset T2DM. The 
incidence probability of T2DM was analyzed using Kaplan-
Meier curves and log-rank test. The two-tailed P values of 
≤0.05 were considered significant. Statistical analyses were per-
formed using SAS version 9.4 (SAS Institute, Cary, NC, USA).
Fig. 1. The process of subject selection by case and control group. T2DM, type 2 diabetes mellitus; CMV, cytomegalovirus; ICD-
10, International Statistical Classification of Diseases and Related-Health Problems 10th Revision; HIRA, the Korean Health In-
surance Review and Assessment Service. aIf patients were died before event occurrence, they were censored.
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RESULTS
Frequencies of chronic diseases between case and control 
group
The overall follow-up duration of all participants was about 3 
years. There was no significant difference in the proportion of 
patients aged ≥60 years and with lower income status between 
case and control group. The case group had significantly higher 
frequency of new-onset T2DM compared to the control group 
(5.6% vs. 2.2%, P<0.001) (Table 1). When we divided the total 
patients (n=3,456) into group with (n=95) new-onset T2DM 
and group without T2DM (n=3,361), the frequency of CMV 
diseases was found to be higher in the group with T2DM 
(33.7% vs. 16.2%, P<0.001) (Supplementary Table 1). The per-
centages of patients with hypertension, dyslipidemia, COPD, 
IHD, cerebral infarction, HF, and ESRD were common in the 
case group (all of P<0.001) (Table 1). 
Impact of CMV diseases on the development of new-onset 
T2DM: subgroup analyses
The incidence rate (IR) per 1,000 T2DM patients in the case 
group was nearly two-fold higher than that in the control 
group at M1 (odds ratio [OR], 2.61; 95% confidence interval 
[CI], 1.69 to 3.96), M2 (OR, 2.60; 95% CI, 1.68 to 3.95), and 
M3 (OR, 2.06; 95% CI, 1.31 to 3.17) (Table 2). Kaplan-Meier 
curve showed that the incidence probability of T2DM in the 
case group was significantly higher than that in the control (P< 
0.001) (Fig. 2A). In the case group, the subgroup aged ≥60 
years had a significantly lower risk of developing T2DM than 
those aged <60 years (M3 [OR, 1.11; 95% CI, 0.50 to 2.20] vs. 
[OR, 3.63; 95% CI, 1.97 to 6.65]; P=0.032, respectively). How-
ever, there was no significant difference in the OR of sex, lower 
income status, hypertension, dyslipidemia, COPD, IHD, cere-
bral infarction, HF, and ESRD (Table 2). 
Difference between refractory and non-refractory CMV 
diseases in T2DM
In a further analysis conducted in three groups with refractory 
CMV diseases, the patients with refractory CMV diseases (M3: 
OR, 4.01; 95% CI, 1.76 to 7.69) had a significantly higher IR of 
T2DM than those without CMV diseases (reference) or with 
non-refractory CMV diseases (M3: OR, 1.77; 95% CI, 1.07 to 
2.82). There was no significant difference in the ORs between 
the three groups according to sex and age (P=0.256 and P= 
0.114, respectively) (Supplementary Table 2). In the Kaplan-
Meier curve of the three groups, patients with refractory CMV 
diseases had the highest IR of T2DM (P<0.001) (Fig. 2B).
Table 1. Comparison of baseline characteristics between adult individuals with and without cytomegalovirus disease in the 
matched cohort
Characteristic
CMV diseases Refractory CMV diseases
Yes (n=576) No (n=2,880) P value Yes (n=88) No (n=488) P value
Male sex 315 (54.69) 1,575 (54.69) >0.999a 54 (61.36) 261 (53.48) 0.172a
Age, yr-old 50.95±15.99 50.95±15.98 >0.999b 51.02±14.13 50.93±16.32 0.962b
   ≥60 164 (28.47) 820 (28.47) >0.999a 21 (23.86) 143 (29.30) 0.298a
Lower income status 154 (26.74) 670 (23.26) 0.074a 26 (29.55) 128 (26.23) 0.518a
Hypertension 226 (39.24) 571 (19.83) <0.001a 29 (32.95) 197 (40.37) 0.190a
Dyslipidemia 132 (22.92) 323 (11.22) <0.001a 19 (21.59) 113 (23.16) 0.748a
COPD 163 (28.30) 363 (12.60) <0.001a 23 (26.14) 140 (28.69) 0.625a
Ischemic heart diseases 147 (25.52) 250 (8.68) <0.001a 23 (26.14) 124 (25.41) 0.807a
Cerebral infarction 45 (7.81) 121 (4.20) <0.001a 6 (6.82) 39 (7.99) 0.784a
Heart failure 64 (11.11) 57 (1.98) <0.001a 7 (7.95) 57 (11.68) 0.361a
ESRD 148 (25.69) 3 (0.10) <0.001a 17 (19.32) 131 (26.84) 0.137a
Follow-up duration, yr 2.92±1.48 3.01±1.43 0.173 2.50±1.53 2.99±1.47 0.004b
Values are presented as number (%) or mean±standard deviation. 
CMV, cytomegalovirus; COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease.
aMcNemar test, bPaired t-test.
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Table 2. Multivariate logistic regression models to examine the effect of adult cytomegalovirus disease on new-onset of type 2 dia-
betes mellitus in various subgroups
CMV 
group
Total 
no.
T2DM 
no.
Total FU 
duration, yr
IRa of 
T2DM Model 1 Model 2 Model 3
P value for 
interaction
Total No 2,880 63 8,664.4 7.27 1 (reference) 1 (reference) 1 (reference) -
Yes 576 32 1,681.4 19.03 2.61 (1.69–3.96) 2.60 (1.68–3.95) 2.06 (1.31–3.17)
Sex 0.408
   Male No 1,575 33 4,737.1 6.97 1 (reference) 1 (reference) 1 (reference)
Yes 315 19 915.7 20.75 2.97 (1.66–5.16) 2.96 (1.66–5.16) 2.17 (1.19–3.84)
   Female No 1,305 30 3,927.3 7.64 1 (reference) 1 (reference) 1 (reference)
Yes 261 13 765.7 16.98 2.21 (1.12–4.15) 2.21 (1.11–4.14) 1.95 (0.96–3.74)
Age, yr-old 0.032
   <60 No 2,060 26 6,357.6 4.09 1 (reference) 1 (reference) 1 (reference)
Yes 412 23 1,228.9 18.72 4.55 (2.58–7.98) 4.59 (2.60–8.04) 3.63 (1.97–6.65)
   ≥60 No 820 37 2,306.8 16.04 1 (reference) 1 (reference) 1 (reference)
Yes 164 9 452.5 19.89 1.24 (0.56–2.45) 1.25 (0.57–2.47) 1.11 (0.50–2.20)
Income 0.422
   Other No 2,210 47 6,659.1 7.06 1 (reference) 1 (reference) 1 (reference)
Yes 422 25 1,202.9 20.78 2.91 (1.77–4.69) 2.81 (1.70–4.52) 2.33 (1.40–3.80)
   Lower 25% No 670 16 2,005.2 7.98 1 (reference) 1 (reference) 1 (reference)
Yes 154 7 478.5 14.63 1.85 (0.71–4.33) 2.02 (0.77–4.75) 1.36 (0.50–3.36)
HTN 0.116
   No No 2,309 30 7,088.7 4.23 1 (reference) 1 (reference) 1 (reference)
Yes 350 14 1,043.4 13.42 3.16 (1.62–5.84) 3.17 (1.63–5.87) 2.92 (1.49–5.44)
   Yes No 571 33 1,575.7 20.94 1 (reference) 1 (reference) 1 (reference)
Yes 226 18 638.0 28.21 1.36 (0.75–2.38) 1.48 (0.80–2.66) 1.47 (0.79–2.64)
DYS 0.384
   No No 2,557 45 7,769.3 5.79 1 (reference) 1 (reference) 1 (reference)
Yes 444 22 1,328.2 16.56 2.87 (1.69–4.71) 2.76 (1.63–4.54) 2.22 (1.29–3.70)
   Yes No 323 18 895.1 20.11 1 (reference) 1 (reference) 1 (reference)
Yes 132 10 353.2 28.32 1.39 (0.62–2.96) 1.36 (0.57–3.06) 1.40 (0.58–3.20)
COPD 0.242
   No No 2,517 54 7,594.3 7.11 1 (reference) 1 (reference) 1 (reference)
Yes 413 19 1,212.8 15.67 2.20 (1.27–3.64) 2.26 (1.31–3.75) 1.69 (0.96–2.86)
   Yes No 363 9 1,070.1 8.41 1 (reference) 1 (reference) 1 (reference)
Yes 163 13 468.6 27.74 3.30 (1.42–7.99) 3.52 (1.51–8.57) 3.35 (1.42–8.22)
IHD 0.625
   No No 2,630 50 7,954.5 6.29 1 (reference) 1 (reference) 1 (reference)
Yes 429 21 1,271.3 16.52 2.62 (1.54–4.30) 2.70 (1.59–4.44) 2.02 (1.17–3.37)
   Yes No 250 13 709.9 18.31 1 (reference) 1 (reference) 1 (reference)
Yes 147 11 410.1 26.83 1.50 (0.66–3.34) 1.51 (0.64–3.47) 1.46 (0.62–3.34)
(Continued to the next page)
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CMV 
group
Total 
no.
T2DM 
no.
Total FU 
duration, yr
IRa of 
T2DM Model 1 Model 2 Model 3
P value for 
interaction
HF 0.642
   No No 2,823 60 8,519.4 7.04 1 (reference) 1 (reference) 1 (reference)
Yes 512 28 1,503.6 18.62 2.64 (1.66–4.09) 2.71 (1.70–4.20) 2.12 (1.32–3.34)
   Yes No 57 3 145.0 20.69 1 (reference) 1 (reference) 1 (reference)
Yes 64 4 177.8 22.50 1.11 (0.25–5.66) 1.02 (0.19–5.73) 1.08 (0.19–6.17)
Cerebral infarction 0.591
   No No 2,759 59 8,314.2 7.10 1 (reference) 1 (reference) 1 (reference)
Yes 531 28 1,563.7 17.91 2.52 (1.59–3.91) 2.58 (1.62–4.00) 2.03 (1.26–3.20)
   Yes No 121 4 350.2 11.42 1 (reference) 1 (reference) 1 (reference)
Yes 45 4 117.6 34.00 2.79 (0.66–11.81) 2.48 (0.57–10.68) 3.40 (0.77–15.21)
ESRD -
   No No 2,877 63 8,656.2 7.28 1 (reference) 1 (reference) 1 (reference)
Yes 428 20 1,249.0 16.01 2.19 (1.29–3.56) 2.10 (1.24–3.41) 1.92 (1.13–3.12)
   Yes No 3 0 8.2 0.00 - - -
Yes 148 12 432.4 27.75 - - -
Values are presented as number or odds ratio (95% confidence interval). Model 1, non-adjusted; Model 2, age- and sex-adjusted; Model 3, age-, 
sex-, lower income-, hypertension-, and dyslipidemia-adjusted.
CMV, cytomegalovirus; T2DM, type 2 diabetes mellitus; FU, follow-up; IR, incidence rate; HTN, hypertension; DYS, dyslipidemia; COPD, 
chronic obstructive pulmonary disease; IHD, ischemic heart disease; HF, heart failure; ESRD, end-stage renal disease.
aPer 1,000. 
Table 2. Continued
Fig. 2. Kaplan-Meier curve for new-onset type 2 diabetes mellitus (T2DM) incidence according to cytomegalovirus (CMV) dis-
ease. (A) Comparison of patients with and without CMV diseases. (B) Comparison of three groups including refractory and non-
refractory CMV diseases (P value of log-lank test). 
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DISCUSSION
This study showed that the occurrence of CMV diseases in-
creases the incidence of new-onset T2DM, with a relative risk 
of ≥200%, which was higher than the CMV-attributable risk of 
CVD evaluated by meta-analyses (22% and 67%) [14,36]. This 
result was identical with additional analysis from the matched 
cohort of 3:1 ratio (1,488 of control group and 496 of case 
CMV disease
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group) with age, sex, cohort entry year, lower income status, 
hypertension, and dyslipidemia as 2.01 of OR (Supplementary 
Table 3). Interestingly, patients aged <60 years had a higher 
risk of T2DM after CMV diseases. However, the existence of 
chronic inflammatory diseases such as hypertension, dyslipid-
emia, COPD, IHD, cerebral infarction, HF, and ESRD did not 
influence the incidence of post-CMV T2DM. These findings 
were consistently derived from different regression models ad-
justed by clinical factors of usual risks for T2DM [37] and con-
founding variables showing higher frequencies in patients with 
CMV diseases (Table 1). The Kaplan-Meier curve indicated 
that most post-CMV T2DM cases developed shortly after 
CMV diseases, in particular, within 1 year.
Majority of epidemiological studies evaluating the causal re-
lationship between CMV and metabolic diseases have focused 
on CVD, especially coronary heart disease (CHD), type I DM, 
and autoimmune diabetes [13,14,36,38]. The meta-analysis 
conducted by Ji et al. [14] revealed that CMV infection was as-
sociated with high risk of CHD. However, only seven (12.7%) 
among the total 55 studies including the meta-analysis report-
ed the detection of CMV DNAemia by PCR [14]. Interestingly, 
the OR reported in seven studies was higher than that in stud-
ies using CMV seroprevalence (8.12 vs. 1.56, respectively) [14]. 
A few studies measuring anti-CMV IgG showed that T2DM 
patients had higher frequency of CMV seropositivity and titer 
(OR, 2 to 12) than healthy subjects [26,27]. In addition, CMV 
seropositive status was associated with higher glucose levels 
[26]. However, these studies may have considerable limitations 
and are underpowered due to the small sample size and rare 
CMV events and because the specific subjects do not reflect 
the universal population.
The pathophysiological mechanisms of post-CMV T2DM 
remain uncertain. Although Lohr and Oldstone [22] revealed 
that CMV genes existed in the pancreatic islets of Langerhans 
cells without cytopathic inflammation and Numazaki et al. 
[39] investigated that CMV was found to replicate in in vitro 
human fetal pancreatic islet cells in the early 1990s, further 
studies had not been reported. Yoneda et al. [38] recently re-
ported that the immunologic indirect effect of CMV infection 
was associated with direct pancreatic β-cell injury, showing T 
lymphocyte infiltration. The reliability of the experiments con-
ducted in human samples was confirmed although the absence 
of CMV in normal controls [22,38]. The discrete impact of 
CMV infection on the failure of islet allografts to support the 
active CMV replication may be an attributing factor to the de-
velopment of T2DM through direct and/or indirect pancreatic 
damages from CMV [40]. On the contrary, we may presume 
that the substances used in the envelop composition such as 
viperin, which is essential to extracellular budding and shed-
ding of complete CMV virion, might alter the lipid and glucose 
metabolism pathways [24]. 
Our new findings of post-CMV T2DM discrepancy by age 
group and early development after CMV diseases could pro-
vide novel insights for the causative effects of CMV replication 
in chronic inflammatory diseases including T2DM. Another 
unique analysis for the refractory nature of CMV diseases, 
which may suggest prolonged active CMV replication, had 
earlier development of and more strong relationship with 
T2DM. The complete lytic reactivation of CMV resulting in 
end-organ cytopathic disease or DNAemia, especially in the 
younger population who have more prominent immunologic 
response than the elderly with profound immunosenescence 
or subjects who have uncontrolled CMV replication, could 
lead to deeper deterioration of immune homeostasis. The 
comprehensive measurement of CMV-specific immunologic 
profiles using mass cytometry (cytometry by time of flight 
[CyTOF]) and genetic evaluation for alteration of glucose me-
tabolism by CMV are warranted. If information regarding 
causative mechanisms in CMV replication and T2DM would 
be accumulated along with further epidemiologic studies in 
various ethnic populations, the development of CMV vaccine 
could be targeted to prevent several chronic inflammatory dis-
eases including T2DM in this era of aging population. 
This study has some limitations, same as those of large-scale 
studies using coding data processing. Therefore, the data col-
lection method could cause the selected disease to be underes-
timated. However, our analyses can overcome this drawback 
through a matched case-control design. In addition, the fre-
quencies of CMV diseases incidence according to ICD-10 code 
showed that our database from the entire population had the 
majority of B25.8 and B25.9 code (1,025 of 1,188, 86.3%), 
which may indicate the confirmatory CMV diagnosis driven 
by pathology in gastrointestinal tract such as esophagus, stom-
ach, duodenum, and colon. The absence of rare cytomegalovi-
ral pancreatitis as well as the minority of cytomegaloviral 
pneumonitis (75 of 1,188, 6.3%), which could be presumptive 
or over-diagnosed with chest computed tomography scan or 
quantitative nucleic acid amplification test in bronchoalveolar 
lavage without standardization and universal cut-off level for 
proper diagnosis, will guarantee the validity of our database for 
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the confirmatory CMV tissue-invasive end-organ disease 
(Supplementary Table 4) [30]. Secondly, our subjects were re-
stricted by South Korean nationality. A previous study showed 
that the effect of CMV infection on CHD might be different 
among ethnic groups, with increased risk among Asian popu-
lations [14]. In addition, the refractory CMV diseases were 
identified simply by repeated administration of anti-CMV 
drugs. The huge database could not allow a more precise defi-
nition of clinical information-based refractory cases in each 
CMV patient. Finally, our cohort includes some proportion of 
solid organ transplantation recipients of about 20% among to-
tal individuals with CMV diseases (Supplementary Table 5). 
However, the patients with new-onset T2DM had higher fre-
quencies of several chronic inflammatory diseases, including 
hypertension, dyslipidemia, IHD, cerebral infarction, and 
ESRD, in the well-known relation to T2DM (Supplementary 
Table 1) [37]. These basic characteristics will ensure the good 
quality in this cohort. In addition, the low IR of CMV end-or-
gan disease in general population may make our population-
based study worthy to evaluate the relationship of CMV and 
T2DM.
In spite of these limitations, our study has several strengths 
and outstanding features: (1) first assessment of the T2DM in-
cidence after CMV diseases including tissue-invasive end-or-
gan damage, but not the CMV serostatus in T2DM patients, 
(2) long wash-out period for ≥4 years that can discriminate 
the casual relationship between CMV diseases and T2DM as 
well as can analyze the post-CMV T2DM, and (3) largest sam-
ple size among studies reporting about the relation between 
T2DM and CMV. 
In conclusion, our data indicate that CMV diseases increase 
the development of T2DM. These results suggest that active 
CMV replication may play an important role in T2DM patho-
genesis.
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Supplementary Table 1. Comparison of clinical characteris-
tics between adult individuals with and without new-onset 
T2DM after cohort entry in the matched cohort of total 3,456
Characteristic
New-onset T2DM 
P valueYes 
(n=95)
No 
(n=3,361)
Male sex 52 (54.74) 1,838 (54.69) 0.992a
Age, yr-old 58.02±12.70 50.75±16.02 <0.001b
   ≥60 46 (48.42) 938 (27.91) <0.001a
Lower income status 23 (24.21) 801 (23.83) 0.932a
Hypertension 51 (53.68) 746 (22.20) <0.001a
Dyslipidemia 28 (29.47) 427 (12.70) <0.001a
COPD 22 (23.16) 504 (15.00) 0.029a
Ischemic heart diseases 24 (25.26) 373 (11.10) <0.001a
Cerebral infarction 8 (8.42) 158 (4.70) 0.095a
Heart failure 7 (7.37) 114 (3.39) 0.038a
End-stage renal disease 12 (12.63) 139 (4.14) <0.001a
CMV diseases 32 (33.68) 544 (16.19) <0.001a
Follow-up duration, yr 1.38±1.19 3.04±1.42 <0.001b
Values are presented as number (%) or mean±standard deviation. 
T2DM, type 2 diabetes mellitus; COPD, chronic obstructive pulmo-
nary disease; CMV, cytomegalovirus.
aMcNemar test, bPaired t-test.
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Supplementary Table 2. Multivariate logistic regression models to examine the effect of refractory cytomegalovirus disease on 
new-onset T2DM in various subgroups
CMV group Total no. T2DM no.
Total FU 
duration, 
yr
IRa of 
T2DM Model 1 Model 2 Model 3
P value for 
interaction
Total No - 2,880 63 8,664.4 7.27 1 (reference) 1 (reference) 1 (reference) -
Yes Non-
refractory
488 24 1,461.2 16.42 2.26 (1.39–3.57) 2.26 (1.38–3.56) 1.77 (1.07–2.82)
Refractory 88 8 220.2 36.34 4.80 (2.12–9.43) 4.84 (2.14–9.53) 4.01 (1.76–7.96)
Sex 0.256
   Male No - 1,575 33 4,737.1 6.97 1 (reference) 1 (reference) 1 (reference)
Yes Non-
refractory
261 15 769.4 19.49 2.80 (1.48–5.05) 2.80 (1.48–5.07) 2.05 (1.06–3.78)
Refractory 54 4 146.3 27.35 3.85 (1.15–9.69) 3.78 (1.13–9.50) 2.75 (0.81–6.70)
   Female No - 1,305 30 3,927.3 7.64 1 (reference) 1 (reference) 1 (reference)
Yes Non-
refractory
227 9 691.8 13.01 1.72 (0.77–3.47) 1.69 (0.76–3.43) 1.46 (0.64–3.03)
Refractory 34 4 73.9 54.14 6.42 (1.91–16.30) 6.88 (2.04–17.53) 6.89 (2.02–17.87)
Age, yr-old 0.114
   <60 No - 2,060 26 6,357.6 4.09 1 (reference) 1 (reference) 1 (reference)
Yes Non-
refractory
345 17 1,062.3 16.00 3.93 (2.09–7.18) 4.04 (2.15–7.38) 3.22 (1.65–6.13)
Refractory 67 6 166.6 36.01 8.27 (3.08–18.80) 7.44 (2.77–16.94) 5.72 (2.07–13.52)
   ≥60 No - 820 37 2,306.8 16.04 1 (reference) 1 (reference) 1 (reference)
Yes Non-
refractory
143 7 399.0 17.55 1.10 (0.45–2.31) 1.10 (0.45–2.32) 0.98 (0.40–2.07)
Refractory 21 2 53.6 37.35 2.25 (0.37–7.36) 2.36 (0.38–7.88) 2.03 (0.33–6.83)
Values are presented as number or odds ratio (95% confidence interval). Model 1, non-adjusted; Model 2, age- and sex-adjusted; Model 3, age-, 
sex-, lower income-, hypertension- and dyslipidemia-adjusted. 
T2DM, type 2 diabetes mellitus; CMV, cytomegalovirus; FU, follow-up; IR, incidence rate. 
aPer 1,000.
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Supplementary Table 3. Comparison of incidence rate of new onset T2DM between adult individuals with and without cyto-
megalovirus disease in the matched cohort of 1:3 ratio with age, sex, cohort entry year, lower income status, hypertension, and 
dyslipidemia
CMV disease Total no. T2DM no. Total FU duration, yr IRa of T2DM OR (95% CI)
No 1,488 41 4,403.6 9.31 1 (reference)
Yes 496 27 1,444.7 18.69 2.01 (1.22–3.24)
T2DM, type 2 diabetes mellitus; CMV, cytomegalovirus; FU, follow-up; IR, incidence rate; OR, odds ratio; CI, confidence interval.
aPer 1,000.
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Supplementary Table 4. Distribution for incidence of cytomegalovirus disease or infection according to ICD-10 codes in the en-
tire-population database
ICD-10 codes
Year
2010 2011 2012 2013 2014
B25 (cytomegalovirus disease) 2 0 1 0 0
B25.0 (cytomegaloviral pneumonitis) 14 14 14 16 17
B25.1 (cytomegaloviral hepatitis) 20 10 10 19 26
B25.2 (cytomegaloviral pancreatitis) 0 0 0 0 0
B25.8 (other cytomegaloviral diseases) 56 77 93 87 123
B25.9 (cytomegaloviral disease, unspecified) 67 105 87 137 193
Total (n=1,188) 159 206 205 259 359
Data were number from the Korean Health Insurance Review and Assessment Service claims data warehouse. 
ICD-10, International Statistical Classification of Diseases and Related-Health Problems 10th Revision.
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Supplementary Table 5. Frequencies of solid organ transplantation recipients 
with CMV disease or infection according to ICD-10 codes between 2010 and 
2015 in the total database
ICD-10 codes
Patients with CMV disease
Total individuals SOT recipients
B25 (cytomegalovirus disease) 3 0 
B25.0 (cytomegaloviral pneumonitis) 89 6 (6.7)
B25.1 (cytomegaloviral hepatitis) 101 4 (4.0)
B25.2 (cytomegaloviral pancreatitis) 4 0 
B25.8 (other cytomegaloviral diseases) 485 80 (16.5)
B25.9 (cytomegaloviral disease, unspecified) 621 193 (31.1)
Total 1,303 283 (21.7)
Values are presented as number (%). 
CMV, cytomegalovirus; ICD-10, International Statistical Classification of Diseases and 
Related-Health Problems 10th Revision; SOT, solid organ transplantation.
